Brian Skorney
Stock Analyst at Baird
(2.16)
# 2,802
Out of 4,898 analysts
113
Total ratings
46.84%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $82.76 | +46.21% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $8.91 | +259.15% | 2 | Jun 18, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $60 → $30 | $19.23 | +56.01% | 11 | Jun 17, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $133.11 | +91.57% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $570.59 | +2.88% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $14.19 | +301.69% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $53.28 | +3.23% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $112.09 | -10.79% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.00 | +130.77% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.42 | +1,087.65% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $6.94 | +188.18% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.60 | +594.44% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.68 | +273.13% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $297.03 | -27.62% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $135.12 | +33.22% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.43 | +532.05% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $33.01 | +87.82% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.70 | +348.28% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $32.61 | +93.19% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $472.35 | -31.20% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $18.59 | -46.21% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.38 | +11,244.54% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.43 | +74.93% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.88 | +15,857.45% | 3 | May 7, 2018 |
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $82.76
Upside: +46.21%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $8.91
Upside: +259.15%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Outperform
Price Target: $60 → $30
Current: $19.23
Upside: +56.01%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $133.11
Upside: +91.57%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $570.59
Upside: +2.88%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $14.19
Upside: +301.69%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $53.28
Upside: +3.23%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $112.09
Upside: -10.79%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.00
Upside: +130.77%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.42
Upside: +1,087.65%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $6.94
Upside: +188.18%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $3.60
Upside: +594.44%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.68
Upside: +273.13%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $297.03
Upside: -27.62%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $135.12
Upside: +33.22%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.43
Upside: +532.05%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $33.01
Upside: +87.82%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.70
Upside: +348.28%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $32.61
Upside: +93.19%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $472.35
Upside: -31.20%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $18.59
Upside: -46.21%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.38
Upside: +11,244.54%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.43
Upside: +74.93%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.88
Upside: +15,857.45%